Mustang Bio, Inc., a clinical-stage biopharmaceutical company in Worcester, reported a net loss of $14.4 million for the company’s second quarter in an earnings report released last Monday.
This new figure shows a slight improvement when compared to the prior-year second quarter, in which the company reported a net loss of $14.6 million.
While profits are down, the press release notes progress in the company’s clinical trials and corporate advancements such as the company’s exclusive license agreement with the Mayo Clinic.
Mustang Bio’s reported assets for the second quarter totaled $143.2 million.
